Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell
- PMID: 29378229
- DOI: 10.1016/j.bbcan.2018.01.005
Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell
Abstract
Natural killer (NK) cells are an important subset of lymphocytes which play a critical role in host immunity against cancers. With MHC-independent recognition, short lifespan and potent cytotoxicity, NK cells make a promising candidate for chimeric antigen receptor (CAR)-engineered cancer immunotherapy. Due to innate biological properties of NK cells, CAR-NK may outperform CAR-T therapy in terms of less side effects and more universal access, which may become a great reformation in CAR-based cancer immunotherapy. The CARs used in peripheral blood (PB) NK cells as well as NK cell line like NK-92 are the most important outfits defining antigenic specificity. The constructs of CARs used in NK cells from different sources vary, which all undergo generational optimization. The anti-tumor effects of CAR-NK have been validated in numerous preclinical trials for cancers, including hematologic malignancies and many solid tumors, which provide evidence for potential clinical application of CAR-NK. Additionally, this review concludes the challenges faced in the application of CAR-NK. Although CAR-NK is considered as one of the most possible "off-the-shelf" products, the improvement for the efficiency of expansion and transduction as well as the solution for underlying safety issues is still needed. Possible coping strategies for challenges and upgrades in techniques are also highlighted for future development in CAR-NK cancer immunotherapy.
Keywords: Cancer; Chimeric antigen receptor; Immunotherapy; Natural killer cell.
Copyright © 2018 Elsevier B.V. All rights reserved.
Similar articles
-
Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy.Acta Pharmacol Sin. 2018 Feb;39(2):167-176. doi: 10.1038/aps.2017.125. Epub 2017 Sep 7. Acta Pharmacol Sin. 2018. PMID: 28880014 Free PMC article. Review.
-
Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV.Protein Cell. 2017 Dec;8(12):861-877. doi: 10.1007/s13238-017-0415-5. Epub 2017 May 9. Protein Cell. 2017. PMID: 28488245 Free PMC article. Review.
-
CAR-NK Cells: From Natural Basis to Design for Kill.Front Immunol. 2021 Dec 14;12:707542. doi: 10.3389/fimmu.2021.707542. eCollection 2021. Front Immunol. 2021. PMID: 34970253 Free PMC article. Review.
-
Engineering Natural Killer Cells for Cancer Immunotherapy.Mol Ther. 2017 Aug 2;25(8):1769-1781. doi: 10.1016/j.ymthe.2017.06.012. Epub 2017 Jun 28. Mol Ther. 2017. PMID: 28668320 Free PMC article. Review.
-
Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer.Expert Opin Biol Ther. 2014 Jul;14(7):947-54. doi: 10.1517/14712598.2014.900540. Epub 2014 Mar 24. Expert Opin Biol Ther. 2014. PMID: 24661086 Review.
Cited by
-
CAR-NK cell therapy for glioblastoma: what to do next?Front Oncol. 2023 Jun 19;13:1192128. doi: 10.3389/fonc.2023.1192128. eCollection 2023. Front Oncol. 2023. PMID: 37404752 Free PMC article. Review.
-
CAR-NK as a Rapidly Developed and Efficient Immunotherapeutic Strategy against Cancer.Cancers (Basel). 2022 Dec 24;15(1):117. doi: 10.3390/cancers15010117. Cancers (Basel). 2022. PMID: 36612114 Free PMC article. Review.
-
Overcoming the challenges in translational development of natural killer cell therapeutics: An opinion paper.Front Oncol. 2022 Dec 2;12:1062765. doi: 10.3389/fonc.2022.1062765. eCollection 2022. Front Oncol. 2022. PMID: 36531041 Free PMC article. No abstract available.
-
Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies.Stem Cell Res Ther. 2022 Sep 24;13(1):482. doi: 10.1186/s13287-022-03163-w. Stem Cell Res Ther. 2022. PMID: 36153626 Free PMC article. Review.
-
The role of the natural killer (NK) cell modulation in breast cancer incidence and progress.Mol Biol Rep. 2022 Nov;49(11):10935-10948. doi: 10.1007/s11033-022-07865-5. Epub 2022 Aug 25. Mol Biol Rep. 2022. PMID: 36008609 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials